Alexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.16, $0.15 better than the analyst estimate of $1.01. Revenue for the quarter came in at $666.6 million versus the consensus estimate of $668.33 million.

Alexion Pharma sees FY2015 EPS of $4.92-$4.97, versus the consensus of $4.82.

“The third quarter of 2015 was a landmark quarter for Alexion as we firmly established our leadership in serving patients with rare and devastating diseases by diversifying our commercial portfolio, advancing the most robust rare disease pipeline in biotech, and continuing to deliver long-term value creation,” said David Hallal, Chief Executive Officer of Alexion. “In the remaining months of 2015, we will continue to grow our core Soliris business in PNH and aHUS, focus on our launches of Strensiq and Kanuma, and will report on several R&D catalysts that are expected in the fourth quarter.”

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.